Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$248.50
+0.9%		$249.60
$186.05
▼
$282.15
$15.36B0.39529,738 shs650,358 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$79.86
-1.7%		$77.36
$46.81
▼
$93.42
$15.88B0.962.01 million shs3.09 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$51.24
+1.2%		$54.19
$33.76
▼
$57.57
$12.70B0.442.73 million shs2.34 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.92%-2.71%-7.47%+3.33%+30.05%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-1.66%-5.47%-3.39%+20.76%+58.52%
Exelixis, Inc. stock logo
EXEL
Exelixis
+1.24%-5.23%-7.76%+2.21%+33.13%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+101.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$248.50
+0.9%		$249.60
$186.05
▼
$282.15
$15.36B0.39529,738 shs650,358 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$79.86
-1.7%		$77.36
$46.81
▼
$93.42
$15.88B0.962.01 million shs3.09 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$51.24
+1.2%		$54.19
$33.76
▼
$57.57
$12.70B0.442.73 million shs2.34 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.92%-2.71%-7.47%+3.33%+30.05%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-1.66%-5.47%-3.39%+20.76%+58.52%
Exelixis, Inc. stock logo
EXEL
Exelixis
+1.24%-5.23%-7.76%+2.21%+33.13%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+101.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.06
Buy$299.2420.42% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$100.7926.21% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.32
Hold$49.79-2.84% Downside
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.00
Hold$14.560.50% Upside

Current Analyst Ratings Breakdown

Latest FOLD, BBIO, ASND, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$280.00 ➝ $290.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $341.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$345.00 ➝ $329.00
8/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$333.00
8/12/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$102.00 ➝ $107.00
8/12/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$104.00 ➝ $106.00
8/12/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$100.00 ➝ $111.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
8/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B) ➝ Buy (A-)
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$110.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$101.00 ➝ $104.00
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.03N/AN/A($2.97) per share-83.67
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$713.07M21.89N/AN/A($12.81) per share-6.23
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.44B5.21$3.06 per share16.72$7.44 per share6.89
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$634.21M7.17$0.06 per share234.67$0.87 per share16.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$8.6719.2821.55N/A70.99%246.61%8.75%N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1816.1113.771.5135.33%42.17%31.76%11/3/2026 (Estimated)
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%N/A

Latest FOLD, BBIO, ASND, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.79
1.00
0.72
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.48
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
1.43
2.84
1.88

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480314.00 million307.09 millionOptionable

Recent News About These Companies

John Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 moves
May 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/john-paulson-s-fund-initiates-amicus-therapeutics-position-dumps-sols-among-q1-moves/ar-AA23jl0v
Amicus Gains Final Approval for BioMarin Acquisition Completion
April 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1509051/amicus-gains-final-approval-for-biomarin-acquisition-completion/
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
April 25, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/04/25/cibra-capital-makes-a-big-merger-arbitrage-bet-on-amicus-therapeutics-fold/
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return
March 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/assessing-amicus-therapeutics-fold-valuation-170354301.html
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
March 26, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260326637556/en/leading-financial-trade-associations-led-by-lsta-submit-amicus-brief-in-support-of-defendant-lenders-in-antitrust-case-filed-by-optumum-communications/
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside
March 15, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/assessing-amicus-therapeutics-fold-valuation-150604642.html
Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD
March 10, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/microsoft-files-amicus-brief-support-anthropics-lawsuit-with-us-dod-2026-03-10/
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio
March 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/amicus-therapeutics-fold-story-shifting-101047780.html
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus
March 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/amicus-therapeutics-buyout-advances-valuation-171014759.html
Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 22,500 Shares
March 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-fold-insider-buying-and-selling-2026-03-05/
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting
March 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/amicus-stockholders-approve-biomarin-acquisition-at-special-meeting?utm_source=marketbeat.com&utm_medium=referral
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus
February 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biomarin-amicus-deal-shifts-rare-031547513.html
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
February 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2873684/amicus-q4-earnings-miss-higher-product-sales-drive-y-y-revenues?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2873684
Amicus Therapeutics: Q4 Earnings Snapshot
February 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/amicus-therapeutics-q4-earnings-snapshot-143818598.html
Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks
February 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/legal-challenges-loom-over-amicus-biomarin-merger-raising-execution-and-shareholder-risks?utm_source=marketbeat.com&utm_medium=referral
Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
February 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67756227-amicus-therapeutics-inc-amicus-therapeutics-announces-full-year-2025-financial-results-and-corporate-updates-399.htm
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
February 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/20/3242137/15991/en/amicus-therapeutics-announces-full-year-2025-financial-results-and-corporate-updates.html
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
February 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/td-cowen-cautious-amicus-therapeutics-003845939.html
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
February 19, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/td-cowen-cautious-amicus-therapeutics-003845939.html
What to Expect From These Drug/Biotech Players This Earnings Season?
February 16, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2870029/what-to-expect-from-these-drug-biotech-players-this-earnings-season?cid=cs-stocknewsapi-ft-analyst_blog|earnings_preview_esp-2870029

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$248.50 +2.27 (+0.92%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$248.19 -0.31 (-0.12%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$79.86 -1.35 (-1.66%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$80.05 +0.19 (+0.24%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$51.24 +0.63 (+1.24%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$51.26 +0.02 (+0.03%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas